

Sucampo Pharmaceuticals Set to Join S&P SmallCap 600

NEW YORK, Feb. 17, 2017 /[PRNewswire](#)/ -- Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) will replace Blue Nile Inc. (NASDAQ: NILE) in the S&P SmallCap 600 effective at the open of Thursday, February 23. Blue Nile was taken private in a transaction completed today.

Sucampo Pharmaceuticals focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders. Headquartered in Rockville, MD, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Pharmaceuticals Sub-Industry index.

Following is a summary of the change:

S&P SMALLCAP 600 INDEX – FEBRUARY 23, 2017			
	COMPANY	GICS ECONOMIC SECTOR	GICS SUB-INDUSTRY
ADDED	Sucampo Pharmaceuticals	Health Care	Pharmaceuticals
DELETED	Blue Nile	Consumer Discretionary	Internet & Direct Marketing Retail

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500[®] and the Dow Jones Industrial Average[®]. More assets are invested in products based on our indices than based on any other provider in the world. With over 1,000,000 indices and more than 120 years of experience constructing innovative and transparent solutions, S&P Dow Jones Indices defines the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

Soogyung Jordan

Global Head of Communications

New York, USA

(+1) 212 438 2297

soogyung.jordan@spdji.com

David Blitzer

Managing Director and Chairman of the Index Committee

New York, USA
(+1) 212 438 3907
david.blitzer@spglobal.com

SOURCE S&P Dow Jones Indices

<http://press.spglobal.com/2017-02-17-Sucampo-Pharmaceuticals-Set-to-Join-S-P-SmallCap-600>